| Expression pattern: |
DN |
| Associated gene: |
CALR, CAPN2 |
| Associated microRNA: |
- |
| Biological function: |
Acts as a tumor suppressor; inhibits HCC cell proliferation, colony formation, DNA synthesis, cell cycle progression, and xenograft tumor growth. |
| Molecular mechanism: |
circATF6 binds CALR and CAPN2, acts as a scaffold to enhance CALR-CAPN2 interaction, promotes CAPN2-mediated CALR degradation, and suppresses CALR-mediated Wnt/beta-catenin signaling. |
| Biological pathway or process: |
Wnt/beta-catenin (inhibits); proliferation (inhibits); cell cycle (inhibits); other pathway/process (promotes) |
| Detected method: |
Q
H
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Microarray; RNA-seq; FISH / smFISH; ISH (In Situ Hybridization); IHC (Immunohistochemistry); IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Cell Cycle Assay; In Vivo Animal Model; H&E Staining; Western Blot; Cohort Study; Survival Analysis; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
circATF6 is a potential prognostic biomarker and therapeutic target for HCC; low expression is associated with poor OS and DFS in the microarray cohort and with worse OS in the qRT-PCR cohort. |
| Description: |
circATF6 is downregulated in HCC and functions as a tumor suppressor. It binds CALR and CAPN2 as a scaffold to promote CALR degradation, thereby inactivating CALR-mediated Wnt/beta-catenin signaling and inhibiting HCC cell growth in vitro and in vivo. Clinically, higher circATF6 expression is associated with better survival, suggesting prognostic and therapeutic value. |
| Confidence score: |
0.9009 |